These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 994932)

  • 41. Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease.
    Gerbracht DD; Steen VD; Ziegler GL; Medsger TA; Rodnan GP
    Arthritis Rheum; 1985 Jan; 28(1):87-92. PubMed ID: 3871330
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J; Legré R; Veit V; Guardia C; Gay AM
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [CRST syndrome (calcinosis cutis--Raynaud's phenomenon--sclerodactylia--telangiectasis)].
    Ohm OJ
    Nord Med; 1970 Feb; 83(9):268-70. PubMed ID: 5426404
    [No Abstract]   [Full Text] [Related]  

  • 45. Raynaud's phenomenon in primary Sjögren's syndrome.
    Skopouli FN; Talal A; Galanopoulou V; Tsampoulas CG; Drosos AA; Moutsopoulos HM
    J Rheumatol; 1990 May; 17(5):618-20. PubMed ID: 2359071
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Total and capillary fingertip blood flow in Raynaud's phenomenon.
    Coffman JD; Cohen AS
    N Engl J Med; 1971 Jul; 285(5):259-63. PubMed ID: 5090397
    [No Abstract]   [Full Text] [Related]  

  • 47. Calcinosis, Raynaud's phenomenon, sclerodactyly, and telangiectasia. The CRST syndrome.
    Schimke RN; Kirkpatrick CH; Delp MH
    Arch Intern Med; 1967 Apr; 119(4):365-70. PubMed ID: 6022520
    [No Abstract]   [Full Text] [Related]  

  • 48. A case of CREST syndrome with rapidly progressive liver damage.
    Yabe H; Noma K; Tada N; Mochizuki S; Nagano M
    Intern Med; 1992 Jan; 31(1):69-73. PubMed ID: 1568046
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Reserpine administration by retrograde intravenous route in patients with Raynaud's phenomenon].
    Acevedo A; Arinoviche R; Palma A; Olea E; Guzmán G; Arriagada M; Grisanti M; Testar R
    Rev Med Chil; 1982 Nov; 110(11):1063-5. PubMed ID: 7184095
    [No Abstract]   [Full Text] [Related]  

  • 50. [Calcinosis-Raynaud's disease-sclerodactylia-telangiectasis syndrome].
    Texier L; Sarrat L; Géniaux M; Gauthier O; Tamisier JM
    Bull Soc Fr Dermatol Syphiligr; 1971; 78(1):53-4. PubMed ID: 5565930
    [No Abstract]   [Full Text] [Related]  

  • 51. Syndrome of sclerodactyly, calcinosis, Raynaud's phenomenon, and telangiectasia.
    Dellipiani AW; George M
    Br Med J; 1967 Nov; 4(5575):334-5. PubMed ID: 6053616
    [No Abstract]   [Full Text] [Related]  

  • 52. Nifedipine in pulmonary arterial hypertension. Importance of Raynaud's phenomenon.
    Fisher J; Mack RJ; Likier HM; Schiff AN; Borer JS
    Chest; 1987 Sep; 92(3):400-5. PubMed ID: 3622018
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
    Zhao H; Lian Y
    Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Treatment of calcinosis circumscripta with probenecid.
    Dent CE; Stamp TC
    Br Med J; 1972 Jan; 1(5794):216-8. PubMed ID: 4621714
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Value and limitations of venous blocks using reserpine in acrosyndromes of the upper extremities].
    Serise JM; Gironnet I; Dugrais G; Janvier G; Winnock S; Boissiéras P
    J Mal Vasc; 1984; 9(2):107-9. PubMed ID: 6747471
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The CRST (calcinosis-Raynaud's disease-scleroderma-telangiectasis) syndrome].
    Szczpański A
    Przegl Dermatol; 1972; 59(1):13-7. PubMed ID: 5061213
    [No Abstract]   [Full Text] [Related]  

  • 57. Simultaneous treatment of Raynaud's phenomenon and orthostatic hypotension.
    Kochar MS
    Am J Med; 1983 Sep; 75(3):537-40. PubMed ID: 6614039
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Pathophysiology and medical treatment of Raynaud's phenomena].
    Adar R
    Harefuah; 1973 Feb; 84(4):227-8. PubMed ID: 4574182
    [No Abstract]   [Full Text] [Related]  

  • 59. The treatment of severe Raynaud's phenomenon with verapamil.
    Kinney EL; Nicholas GG; Gallo J; Pontoriero C; Zelis R
    J Clin Pharmacol; 1982 Jan; 22(1):74-6. PubMed ID: 7037872
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Remission of Raynaud's phenomenon after L-thyroxine therapy in a patient with hypothyroidism.
    Lateiwish AM; Fehér J; Baraczka K; Rácz K; Kiss R; Gláz E
    J Endocrinol Invest; 1992 Jan; 15(1):49-51. PubMed ID: 1560191
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.